This difference is one reason researchers model the two compounds on different schedules and often place BPC-157 near the tissue of interest

Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
It's not an iron though, its not going to take all of the lines away
MIC B12 injections are a targeted blend of lipotropic nutrients designed to support metabolism, liver function, and energy production
A role for a 70-kilodaton heat shock protein in lysosomal degradation of intracellular proteins
BPC-157 is injected, either into subcutaneous fat on the belly or directly into the targeted area, like an injured knee or shoulder